Drugs / PINTA 745
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01958970 | Jan 2014 → Nov 2015 | end stage renal failure, protein-energy malnutrition | Pinta Biotherapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PINTA 745 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01958970 ↗ |
| Action | Inhibit | “Anti-myostatin” NCT01958970 ↗ |
| Modality | Peptide | “Anti-myostatin Peptibody” NCT01958970 ↗ |
| Route | Intravenous | “PINTA 745 will be administered once weekly by IV infusion.” NCT01958970 ↗ |